RNAC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
-100.0%
78.0K
-91.8%
947.0K
+109.5%
452.0K
+51.7%
298.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
78.0K
-91.8%
947.0K
+109.5%
452.0K
+51.7%
298.0K
Operating Expenses
29.2M
+9.7%
26.6M
-66.6%
79.6M
+269.9%
21.5M
-2.7%
22.1M
R&D
20.4M
+5.0%
19.5M
+32.5%
14.7M
+6.4%
13.8M
-7.2%
14.9M
SG&A
8.7M
+22.6%
7.1M
-13.2%
8.2M
+6.2%
7.7M
+6.6%
7.2M
Operating Income
-29155000
-10.0%
-26499000
+66.3%
-78639000
-273.3%
-21066000
+3.4%
-21811000
EBITDA
-28376000
-9.6%
-25884000
-21.3%
-21331000
-4.3%
-20460000
+3.6%
-21222000
Net Income
15.8M
+140.2%
-39182000
+57.7%
-92576000
-157.9%
-35902000
-326.0%
15.9M
EPS (Basic)
$0.47
+132.2%
$-1.46
+59.0%
$-3.56
-158.0%
$-1.38
-370.6%
$0.51
EPS (Diluted)
$0.46
+131.5%
$-1.46
+59.7%
$-3.62
-162.3%
$-1.38
-376.0%
$0.50
Shares (Diluted)
29.9M
+11.2%
26.9M
+5.1%
25.5M
-1.8%
26.0M
-1.7%
26.4M
Cartesian Therapeutics (RNAC) โ€” Financials